Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women

Journal of Clinical Pharmacology

Volumn 47, Issue 10, 2007, Pages 1292-1302

  Karara, Adel H ^a,c   Hanes, Vladimir ^a   Alonso, Alberto ^b   Ni, Pingping ^a   Poola, Nagaraju ^a   Silang, Rose ^a   Blode, Hartmut ^a   Preston, Richard A ^b  

^a BAYER PHARMA AG   (Germany)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

Aldosterone; Aldosterone antagonists; Diuretics; Drospirenone; Drug interactions; Estradiol; Hormone therapy; Hydrochlorothiazide; Hypertension; Potassium; Progesterone; Progestogens

Indexed keywords

ALDOSTERONE; DROSPIRENONE; DROSPIRENONE PLUS ESTRADIOL; ESTRADIOL; GESTAGEN; HYDROCHLOROTHIAZIDE; PLACEBO; POTASSIUM;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; GEOMETRY; HORMONAL THERAPY; HUMAN; HYPERTENSION; HYPOTENSION; MASTALGIA; PLASMA RENIN ACTIVITY; POSTMENOPAUSE; POTASSIUM BLOOD LEVEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VAGINA BLEEDING;

AGED; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANDROSTENES; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MIDDLE AGED; POSTMENOPAUSE; POTASSIUM;

EID: 34748878206     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007306560     Document Type: Article

References (30)

1. Muhn P., Fuhrmann U., Fritzemeier KH, Krattenmacher R., and Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci. 1995 ; 761: 311-335.
2. Oelkers W. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995 ; 80: 1816-1821.
3. Fuhrmann U., Krattenmacher R., Slater EP, Fritzemeier KH The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996 ; 54: 243-251.
4. Oelkers W. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids. 1996 ; 61: 166-171.
5. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 ; 62: 29-38.
6. Archer DF, Thorneycroft IH, Foegh M., et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005 ; 12: 716-727.
7. Preston RA, Alonso A., Panzitta D., Zhang P., Karara AH Additive effect of drospirenone /17-beta estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens. 2002 ; 15: 816-822.
8. Preston RA, White WB, Pitt B., Bakris G., Norris PM, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005 ; 18: 797-804.
9. White WB, Pitt B., Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17-beta-estradiol, a novel hormone treatment in post-menopausal women with stage 1 hypertension. Circulation. 2005 ; 112: 1979-1984.
10. White WB, Hanes V., Chauhan V., Pitt B. Effects of a new hormone therapy, drospirenone and 17-ß-estradiol, in post-menopausal women with hypertension. Hypertension. 2006 ; 48: 246-253.
11. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 ; 42: 1206-1252.
12. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 ;289: 2560-2572.
13. Allhat Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002 ; 288: 2981-2997.
14. Salvetti A., Ghiadoni L. Thiazide diuretics in the treatment of hypertension: an update. J Am Soc Nephrol. 2006 ; 17: 25-29.
15. Cockcroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron. 1976 ; 16: 31-41.
16. Preston RA, Norris PM, Alonso AB, Ni P., Hanes V., Karara AH Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause. 2007 ; 14: 408-414.
17. Schriffrin EL Effects of aldosterone on the vasculature. Hypertension. 2006 ; 47: 312-318.
18. Farquiharson Caj, Struthers AD Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000 ; 101: 594-597.
19. Grandi AM, Imperiale D., Santillo R., et al. Aldosterone antagonist improves diastolic dysfunction in essential hypertension. Hypertension. 2002 ; 40: 647-652.
20. Rocha R., Chander PN, Khanna K., Zuckerman A., Stier CT Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998 ; 31: 451-458.
21. MacFadyen RJ, Barr CS, Struthers AD Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997 ; 35: 30-34.
22. White WB, Duprez D., St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003 ; 41: 1021-1026.
23. White WB, Carr AA, Krause S., Jordan R., Roniker B., Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol. 2003 ; 92: 38-42.
24. Chrysostomou A., Pedagogos E., MacGregor L., Becker GJ Double-blind, placebo controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol. 2006 ; 1: 256-262.
25. Pitt B., Zannad F., Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999 ; 341: 709-717.
26. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 ; 348: 1309-1321.
27. Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002 ; 288: 321-333.
28. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004 ; 291: 1701-1712.
29. Wassertheil-Smoller S., Hendrix SL, Limacher M., et al, for the WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA. 2003 ; 289: 2673-2684.
30. Steiner AZ, Hodis HN, Lobo RA, Shoupe D., Xiang M., Mack WJ Postmenopausal oral estrogen therapy and blood pressure in normotensive and hypertensive subjects: The Estrogen in the Prevention of Atherosclerosis Trial. Menopause. 2005 ; 12: 728-733.